PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.

Trial Details

NCT ID

NCT06274047

Phase

PHASE3

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Apalutamide
Androgen Deprivation Therapy

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Chicago, Illinois, United States|41.85003,-87.65005
Kansas City, Kansas, United States|39.11417,-94.62746
Boston, Massachusetts, United States|42.35843,-71.05977
New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Histologically confirmed prostate cancer.
PSA ≥ 0.1 after radical prostatectomy.
Candidate for salvage radiation and ADT treatment, as determined by treating physician.
Age \>18 at the time of consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →